Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Ratio (2018 - 2025)

X4 Pharmaceuticals' Equity Ratio history spans 8 years, with the latest figure at 0.64 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 324.06% year-over-year to 0.64; the TTM value through Dec 2025 reached 0.64, up 324.06%, while the annual FY2025 figure was 0.64, 324.06% up from the prior year.
  • Equity Ratio reached 0.64 in Q4 2025 per XFOR's latest filing, up from 0.38 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.65 in Q1 2021 to a low of 0.01 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.4, with a median of 0.4 recorded in 2023.
  • Peak YoY movement for Equity Ratio: crashed 97.78% in 2024, then skyrocketed 1810.93% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.55 in 2021, then dropped by 13.42% to 0.48 in 2022, then fell by 27.09% to 0.35 in 2023, then tumbled by 56.41% to 0.15 in 2024, then skyrocketed by 324.06% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Equity Ratio are 0.64 (Q4 2025), 0.38 (Q3 2025), and 0.04 (Q2 2025).